2025 International Symposium of Gastrointestinal Oncology (ISGIO)

Breakfast

Resectable Pancreatic Cancer With No Vascular Involvement: Is There a Role for Neoadjuvant Therapy?

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic PDAC

Promising Therapeutic Targets in a Rapidly Changing Landscape in Advanced PDAC

Sequencing Therapy for Advanced GEP-NETs in 2025

Integrating Predictive Molecular Biomarkers in the Potentially Curative Setting for Nonfunctional pNETs

The Emerging Role of Transplant for Intrahepatic Cholangiocarcinoma

HER2 Targeting in Biliary Tract Cancers: How to Test, How to Exploit

Case Presentation: Unresectable, Nonmetastatic HCC

Integrating IO-Based Therapies in Patients With HCC Eligible for Arterial Embolization: Are We There Yet?

Expanding the Role of Immune-Based Therapies Beyond CPI in Advanced HCC

Bridging Immunotherapy and Surgery for Resectable EG Cancers: Who Is a Candidate?

Navigating the Growing Complexity of Therapeutic Targeted Approaches in Advanced EG Cancers

Case Presentation: Optimizing Neoadjuvant Therapy and Panel Discussion

Spotlight CE Session: Pathways to Progress: RAS in GI Cancers

Breakfast and Non-CE Product Theater: A Treatment Option for MSI-H/dMMR Patients with Unresectable or Metastatic Colorectal Cancer

Chemotherapy Alone in Early-Stage Rectal Cancer: When Can We Avoid Radiation?

Survivorship in Colon and Rectal Cancer: What Is the Best Way to Prevent Recurrence?

Medical Crossfire® in MSI-H Colon Cancer: Neoadjuvant Immunotherapy or Not?

Keynote Address: Precision Medicine Transforms Cancer Care

Lunch and Non-CE Product Theater: The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade

Hitting Biology in Earlier Lines of Therapy

Immunotherapy in Patients With Nonliver Metastatic CRC

Immunotherapy for Anal Cancer: How Far Have We Come?

Advanced CRC Tumor Board and Panel Discussion